Skip to content
DataLookout
Menu

NCT02787369

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 10 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Apr 2026 to Jun 2019
    • Eligibility criteria expanded, about 5 words
    • Trial completed
    • Study completion date changed from estimate of Apr 2027 to Mar 2023
  2. Notable Primary completion date: Apr 2024 to Apr 2026
    • Study completion date: Apr 2026 to Apr 2027
    v13
  3. Notable Primary completion date: Apr 2022 to Apr 2024
    • Study completion date: Apr 2023 to Apr 2026
    • Study description revised
    v9
  4. Notable Primary completion date: Apr 2021 to Apr 2022v8
  5. Notable Primary completion date: Apr 2020 to Apr 2021
    • Study completion date: Apr 2022 to Apr 2023
    v7
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Apr 2019 to Apr 2020v6
  2. Minor Secondary endpoints: details revised at 4 of 4 entriesv5
  3. Notable Enrollment target: estimated 56 to confirmed 3
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determining Maximum Tolerated Dose
Timeframe: 2 years

Secondary (4)

Clinical Response Rate
Best Overall Response Rate
Progression Free Survival Rate
Overall Survival Rate

Arms and interventions

Combination of ACY-1215 With IbrutinibExperimental

ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.

Combination of ACY-1215 With IdelalisibExperimental

ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.

Drugs: ACY-1215, Ibrutinib, Idelalisib

Sites

1 site in 1 country

  • Dana Farber Cancer InstituteBoston, Massachusetts, United States